Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 521 participants.
Also called NCT01123980
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 521 participants
- Sponsor
- Registry
-
NCT01123980
-
- Other papers using this trial's data
- Treat-to-target comparison between once daily biphasic insulin aspart 30 and insulin glargine in Chinese and Japanese insulin-naïve subjects with type 2 diabetes
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China, Japan
- Registry status
- Completed
Technical summary
Registry record NCT01123980. Randomized; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2011-06 (actual). Results posted on 2012-07-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment
- Acronym
- EasyMix
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- biphasic insulin aspart 30
- Intervention (Drug)
- metformin
- Intervention (Drug)
- glimepiride
- Intervention (Drug)
- insulin glargine
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01123980- Content hash
fa6f55cb60441d3b870632914ff75ab7ef92eae02cb91eb4cb6e247e797fdfff